VJHemOnc is committed to improving our service to you

ASH 2019 | Fimepinostat with venetoclax in R/R lymphoma

VJHemOnc is committed to improving our service to you

Anas Younes

Anas Younes, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines the interesting synergistic anti-tumor effects of fimepinostat (CUDC-907), a dual inhibitor of phosphotidyl-inositol-3-kinases (PI3Ks) and Class I and II histone deacetylases (HDACs), in combination with venetoclax, a BCL2 inhibitor. This novel combination targeting MYC and BCL2 was recently evaluated in a phase 1/2, multi-center, dose-finding trial (NCT01742988), in patients with relapsed/refractory (R/R) lymphoma, R/R diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter